227 abstracts found.



Results filter



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain



Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK



The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA



What use are clinical trials to young people? Lessons from UK trial accrual 2005-2009

Year:

Session type:

Jeremy Whelan
University College Hospitals, London, United Kingdom



Specialist services for TYA with cancer: how do they contribute to better outcomes

Year:

Session type:

Faith Gibson
Great Ormond Street Hospital for Children and London South Bank University, London, United Kingdom



Setting the research agenda with young people

Year:

Session type:

NCRI Teenage & Young Adult Core Consumer Group1
National Cancer Research Institute, London, United Kingdom



Introduction: Tumour microenvironment and inflammation

Year:

Session type:

Fran Balkwill
Barts and the London School od Medicine and Dentistry, UK



Sex, fat and infections: The molecular pathogenesis of hepatocellular carcinoma and inflammation linked cancer

Year:

Session type:

Michael Karin
UC San Diego, La Jolla, United States



Inflammation induced liver cancer: a lymphotoxin driven pathway to hepatocellular carcinoma

Year:

Session type:

Mathias Heikenwälder
Department of Pathology, Zürich, Switzerland



Introduction: Pathway specific therapeutics

Year:

Session type:

Richard Marais
The Institute of Cancer Research, London, UK



Mechanisms of stromal cell recruitment

Year:

Session type:

Robert A Weinberg
Whitehead Institute for Biomedical Research, Massachusetts, United States



The biology and therapeutic implications of BRAF and RAS signalling in cancer

Year:

Session type:

Richard Marais
The Institute of Cancer Research, London, United Kingdom



Cellular responses to DNA damage: new molecular insights and new opportunities for cancer therapy

Year:

Session type:

Steve Jackson
University of Cambridge, UK



A chemical-genetic approach to melanocyte stem cells: a novel role for the Prl-3 phosphatase

Year:

Session type:

Elizabeth Patton
Edinburgh Cancer Research Centre, Edinburgh, UK



Deciphering the mammary epithelial cell hierarchy

Year:

Session type:

John Stingl
CRUK Cambridge Research Institute, Cambridge, United Kingdom



Generation of leukaemia cell hierarchies by MLL fusion oncogenes

Year:

Session type:

Tim Somervaille
Paterson Institute for Cancer Research, Manchester, United Kingdom



Phenotypic Heterogeneity and Instability of Human Ovarian Tumor-Initiating Cells

Year:

Session type:

Benjamin Neel
Ontario Cancer Institute, Toronto, Canada



Introduction: Stem cells and cancer

Year:

Session type:

Tariq Enver
UCL Cancer Institute, UK



Introduction: Teenagers and young adults

Year:

Session type:

Jeremy Whelan
University College London, UK



An analysis of factors affecting survival in adolescents and young adults with cancer

Year:

Session type:

David Thomas
Peter MacCallum Cancer Centre, Melbourne, Australia



MDCT volume measurement as a diagnostic tool in lung cancer screening

Year:

Session type:

Matthijs Oudkerk
BCN / University of Groningen, The Netherlands



Minichromosome maintenance proteins in cancer screening

Year:

Session type:

Nick Coleman
Medical Research Council, Cambridge, United Kingdom



Introduction: Hard to beat cancers: when can we expect progress?

Year:

Session type:

Herbie Newell
Northern Institute for Cancer Research, University of Newcastle, UK



Personalised therapy for lung cancer

Year:

Session type:

Scott Gettinger
Yale University, Connecticut, USA



Incorporating targeted therapy into oesophagogastric cancer management

Year:

Session type:

David Cunningham
Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom



Developing pancreatic cancer medicines

Year:

Session type:

David Tuveson
Cancer Research UK, Cambridge, United Kingdom



Title to be confirmed

Year:

Session type:

John Heymach
The University of Texas MD Anderson Cancer Center, Houston, USA



Introduction: Biomarkers and imaging

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK



Circulating tumour cells

Year:

Session type:

Johann Sebastian de Bono
The Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom